Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MTOR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MTOR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MTOR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MTOR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004592717 | Esophagus | ESCC | positive regulation of growth | 137/8552 | 259/18723 | 1.13e-02 | 3.80e-02 | 137 |
GO:00516478 | Esophagus | ESCC | nucleus localization | 17/8552 | 24/18723 | 1.13e-02 | 3.81e-02 | 17 |
GO:190303617 | Esophagus | ESCC | positive regulation of response to wounding | 43/8552 | 72/18723 | 1.14e-02 | 3.84e-02 | 43 |
GO:00031793 | Esophagus | ESCC | heart valve morphogenesis | 34/8552 | 55/18723 | 1.16e-02 | 3.90e-02 | 34 |
GO:00456872 | Esophagus | ESCC | positive regulation of glial cell differentiation | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
GO:00140131 | Esophagus | ESCC | regulation of gliogenesis | 59/8552 | 103/18723 | 1.17e-02 | 3.91e-02 | 59 |
GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
GO:00346372 | Esophagus | ESCC | cellular carbohydrate biosynthetic process | 46/8552 | 78/18723 | 1.24e-02 | 4.13e-02 | 46 |
GO:009030310 | Esophagus | ESCC | positive regulation of wound healing | 36/8552 | 59/18723 | 1.27e-02 | 4.21e-02 | 36 |
GO:00427529 | Esophagus | ESCC | regulation of circadian rhythm | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
GO:19040197 | Esophagus | ESCC | epithelial cell apoptotic process | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
GO:00353132 | Esophagus | ESCC | wound healing, spreading of epidermal cells | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
GO:001821010 | Esophagus | ESCC | peptidyl-threonine modification | 70/8552 | 125/18723 | 1.29e-02 | 4.25e-02 | 70 |
GO:00031703 | Esophagus | ESCC | heart valve development | 39/8552 | 65/18723 | 1.41e-02 | 4.59e-02 | 39 |
GO:00303165 | Esophagus | ESCC | osteoclast differentiation | 54/8552 | 94/18723 | 1.43e-02 | 4.65e-02 | 54 |
GO:190274515 | Esophagus | ESCC | positive regulation of lamellipodium organization | 24/8552 | 37/18723 | 1.46e-02 | 4.74e-02 | 24 |
GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:001603212 | Liver | Cirrhotic | viral process | 203/4634 | 415/18723 | 5.40e-27 | 3.76e-24 | 203 |
GO:001905812 | Liver | Cirrhotic | viral life cycle | 148/4634 | 317/18723 | 1.12e-17 | 1.64e-15 | 148 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTOR | SNV | Missense_Mutation | novel | c.7184A>G | p.Asn2395Ser | p.N2395S | P42345 | protein_coding | tolerated(1) | possibly_damaging(0.703) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MTOR | SNV | Missense_Mutation | | c.7498N>T | p.Ile2500Phe | p.I2500F | P42345 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MTOR | SNV | Missense_Mutation | rs769877976 | c.25G>A | p.Ala9Thr | p.A9T | P42345 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.835) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MTOR | SNV | Missense_Mutation | novel | c.6287N>T | p.Asp2096Val | p.D2096V | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.3142A>C | p.Ile1048Leu | p.I1048L | P42345 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.5276N>G | p.Leu1759Arg | p.L1759R | P42345 | protein_coding | tolerated(0.51) | probably_damaging(0.995) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
MTOR | SNV | Missense_Mutation | | c.397N>G | p.Leu133Val | p.L133V | P42345 | protein_coding | deleterious(0) | possibly_damaging(0.563) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | | c.4835N>C | p.Arg1612Pro | p.R1612P | P42345 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | novel | c.3722N>G | p.Gln1241Arg | p.Q1241R | P42345 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | | c.7162N>C | p.Glu2388Gln | p.E2388Q | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | QUINACRINE | QUINACRINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | BEZ235 | DACTOLISIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | TCMDC-125575 | CHEMBL587620 | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PERPHENAZINE | PERPHENAZINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | 24625776 |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | 249565693 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | CAFFEIC ACID PHENETHYL ESTER | CAFFEIC ACID PHENETHYL ESTER | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | AZD2014 | VISTUSERTIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | GDC-0980/RG7422 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | EVEROLIMUS | EVEROLIMUS | 24625776,25295501 |